Result: The remaining 8% of viruses with predicted intermediate or high-level LPV resistance had a combination of two or more PI DRMs with lower mutation scores, including V32I, M46I, I54M/L/V, I47V, V82S/T/M and L90M.
Table: M46I
Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens.
Result: At VF, the following major treatment-emergent PI mutations or mutation mixtures were detected: M46M/I, I50I/V, I54I/M/V, and I84I/V, and the virus developed FPV RS.
2014 Update of the drug resistance mutations in HIV-1.
Discussion: Results from the HIV-1 drug resistance mutation research by the International AIDS Society-USA (updated in March 2013) have revealed that PI resistance mutation sites are L10I, K20M, V32I, M36I, M46I/L, I47V/A, I50V, Q58E, A71V, G73S, V82A/F/T, I84V, L89V,L90M; NRTIs resistance mutations are M41L, A62V, PMID: 24629078
2014
BMC bioinformatics
Result: The L63P mutation has a compensatory effect that increases catalytic activity from 110% to 530%; when L63P is associated with M46I, it forms a combination that is resistant to APV, IDV, LPV or NFV.
Result: We modelled the proteins with unusual mutations (L5F, D29V, L63G, L63R, P79L and T91V), natural polymorphisms (L63H andL63S), and drug-resistant mutant PRs with single mutations or patterns of mutations (D30N, V32I, M36I, M46I, I47V,
HIV-1 pol diversity among female bar and hotel workers in Northern Tanzania.
Result: In the protease gene, three subjects (7%) had major mutations at position 46 (M46I/L) associated with PR drug resistance mutations (Table 3).
Table: M46I
Discussion: Since PIs were not used in Tanzania at the time that the samples were collected, the mutations M46I and M46L most likely represent natural polymorphisms rather than transmitted drug-resistant strains.
Discussion: Three (7%) subjects had a major mutation at the protease amino acid position 46 (M46I/L) that confers high resistance to protease inhibitors (PIs) only in combination with other mutations, and can occur a
Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro.
Method: Laboratory adaptive strains, including HIV-1IIIB, HIV-1RF, HIV-1 reverse transcriptase (RT) resistant strain, HIV-1LAI-M184V and HIV-1L74V, fusion inhibitor resistant strain pNL4-3gp41 (36G) V38A/N42T, HIV proteaseGene Mutants HIV-1RF/V82F/184V and HIV-1L10R/M46I/L63P/V82T/I84V were kindly donated by NIH.
Result: FNC and 3TC were both sensitive to NRTIs-resistant strain HIV-174V, PIs-resistant strains HIV-1L10R/M46I/L63P/V82T/I84V and HIV-1RF V82F/184V, and FIs-resistant strain pNL4-3 gp41 (36G) V38A/N42T (Table 1).
Table: M46I
A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses.
Result: Of the 243 patients who received one or more protease inhibitors, 32 (13%) had a study-defined protease inhibitor-resistance mutation most commonly L10F, K20T, V32I, L33F, M46I/L, I47V/A, I50L, F53L, I54V/L, Q58E, L76V, V82A/C, I84V, L89V, and L90M.
Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses.
PMID: 25397500
2014
Journal of the International AIDS Society
Table: M46I
A significant reduction in the frequency of HIV-1 drug resistance in Quebec from 2001 to 2011 is associated with a decrease in the monitored viral load.
Result: The most common primary mutations associated with ARV resistance in TE individuals ( Figure 2 ) were NRTIs: M184I/V (51.1%) and thymidine analog mutations (TAM) from TAM1 pathway (41L/210W/215Y; 17%), representing 76.2% of all TAM pathways (data not shown); NNRTIs: K103N (24.9%); PIs: L90 M (21.1%), V82 (16.8%), M46I/L (18.2%).
HIV mutation literature information.
PMID: 
2015
PloS one
Browser Board
Co-occurred Entities
Filtrator
ViMRT